Profiles of B and T cell immune responses elicited by different forms of the hepatitis B virus surface antigen

[Guest guest]

http://www.sciencedirect.com/science?_ob=ArticleURL & _udi=B6TD4-5100NHW-2 & _user=1\

0 & _coverDate=10%2F21%2F2010 & _rdoc=10 & _fmt=high & _orig=browse & _origin=browse & _zone\

=rslt_list_item & _srch=doc-info(%23toc%235188%232010%23999719954%232484761%23FLA%\

23display%23Volume) & _cdi=5188 & _sort=d & _docanchor= & _ct=16 & _acct=C000050221 & _versi\

on=1 & _urlVersion=0 & _userid=10 & md5=075e46571c7bb90a41bb532d0de0464b & searchtype=a

Vaccine

Volume 28, Issue 45, 21 October 2010, Pages 7288-7296

--------------------------------------------------------------------------------

doi:10.1016/j.vaccine.2010.08.081 | How to Cite or Link Using DOI

Elsevier Ltd All rights reserved.

Permissions & Reprints

Profiles of B and T cell immune responses elicited by different forms of the

hepatitis B virus surface antigen

References and further reading may be available for this article. To view

references and further reading you must purchase this article.

Meilong Shena, b, c, Shixia Wangc, d, Guohong Gea, b, c, Yiping Xinga, b, c,

Xiuwen Mad, Zuhu Huanga, b, c, and Shan Lub, c, d, ,

a Department of Infectious Diseases, First Affiliated Hospital, Nanjing Medical

University, Nanjing 210029, China

b Jiagnsu Province Key Laboratory in Infectious Diseases, First Affiliated

Hospital, Nanjing Medical University, Nanjing 210029, China

c China–US Vaccine Research Center, First Affiliated Hospital, Nanjing Medical

University, Nanjing 210029, China

d Laboratory of Nucleic Acid Vaccines, Department of Medicine, University of

Massachusetts Medical School, Worcester, MA 01605, USA

Received 3 February 2010; revised 18 August 2010; accepted 22 August 2010.

Available online 8 September 2010.

Abstract

Gene-based hepatitis B virus (HBV) vaccines have been proposed as a novel

approach to improve the immunogenicity toward non-responders and to allow for

protection against potential viral escape mutants. Furthermore, there is

significant interest in using DNA or viral vector vaccines to serve as

therapeutic agents to treat chronic HBV infections that are resistant to

existing drug therapies. However, the key protective antigen of HBV, the surface

protein (HBsAg), can be expressed in three different sizes due to its multiple

translational initiation sites: small, middle, and large forms of HBsAg. It is

not clear whether the immunogenicity of these HBsAg is same, especially their

ability to elicit HBsAg-specific B cell and T cell immune responses in addition

to the traditional serum HBsAg-specific antibody responses. In the current

study, the immunogenicity of three forms of HBsAg DNA vaccines was analyzed

individually in a mouse model. Our results indicated that different forms of the

HBsAg have unique immunogenicity profiles and this information is useful for the

selection of optimal gene-based HBV vaccines for further improved prophylactic

and therapeutic applications.